TrialArthritis research & therapy2017

Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.

T W J Huizinga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.